Nipple aspirate fluid proteome of healthy females and patients with breast cancer

Clinical Chemistry

Volumn 56, Issue 5, 2010, Pages 848-855

  Pavlou, Maria P ^a,b,c   Kulasingam, Vathany ^a,b,c   Sauter, Edward R ^d   Kliethermes, Beth ^d   Diamandis, Eleftherios P ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MEMBRANE PROTEIN; PROTEASOME; TUMOR MARKER;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BREAST CANCER; CASE REPORT; CONTROLLED STUDY; FEMALE; FRACTIONATION; HUMAN; HUMAN TISSUE; MAMMARY GLAND; MASS SPECTROMETER; MASS SPECTROMETRY; NIPPLE ASPIRATION; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEOMICS;

BREAST; BREAST NEOPLASMS; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; NIPPLE ASPIRATE FLUID; PROTEINS; PROTEOME; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 77951746656     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.136283     Document Type: Article

References (38)

1. Keynes G. Chronic mastitis. Br J Surg 1923;11:89-121.
2. Papanicolaou GN, Bader GM, Holmquist DG, Falk EA. Cytologic evaluation of breast secretions. Ann NY Acad Sci 1956;63:1409-1421
3. Fleming RM. Cytological studies in lesions of the breast: findings in nipple secretions and aspirates from tumors. South Med J 1955;48:74-78
4. Sauter ER. Analysis of nipple aspirate fluid for diagnosis of breast cancer: an alternative to invasive biopsy. Expert Rev Mol Diagn 2005;5:873-881
5. Malatesta M, Mannello F, Bianchi G, Sebastiani M, Gazzanelli G. Biochemical and ultrastructural features of human milk and nipple aspirate fluids. J Clin Lab Anal 2000;14:330-335
6. Petrakis NL. ASPO Distinguished Achievement Award Lecture: studies on the epidemiology and natural history of benign breast disease and breast cancer using nipple aspirate fluid. Cancer Epidemiol Biomarkers Prev 1993;2:3-10.
7. Russo J, Furmanski P, Bradley R, Wells P, Rich MA. Differentiation of normal human mammary epithelial cells in culture: an ultrastructural study. Am J Anat 1976;145:57-77.
8. Rennison ME, Handel SE, Wilde CJ, Burgoyne RD. Investigation of the role of microtubules in protein secretion from lactating mouse mammary epithelial cells. J Cell Sci 1992;102:239-247
9. Fabian CJ, Kimler BF, Mayo MS, Khan SA. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 2005;12:185-213. (Pubitemid 40903084)
10. Wrensch MR, Petrakis NL, Gruenke LD, Ernster VL, Miike R, King EB, Hauck WW. Factors associated with obtaining nipple aspirate fluid: analysis of 1428 women and literature review. Breast Cancer Res Treat 1990;15:39-51. (Pubitemid 20139597)
11. Suijkerbuijk KP, van der WE, van Diest PJ. Oxytocin: bringing magic into nipple aspiration. Ann Oncol 2007;18:1743-1744
12. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer 2005;114:791-796 (Pubitemid 40344440)
13. Luo LY, Grass L, Howarth DJ, Thibault P, Ong H, Diamandis EP. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem 2001;47:237-246 (Pubitemid 32142922)
14. He J, Gornbein J, Shen D, Lu M, Rovai LE, Shau H, et al. Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatographytandem mass spectrometry. Int J Oncol 2007;30:145-154
15. Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM. Proteomic analysis of nipple aspirate fluid from women with early stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 2006;6:68.
16. Varnum SM, Covington CC, Woodbury RL, Petritis K, Kangas LJ, Abdullah MS, et al. Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res Treat 2003;80:87-97. (Pubitemid 36851288)
17. Alexander H, Stegner AL, Wagner-Mann C, Du Bois GC, Alexander S, Sauter ER. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 2004;10:7500-7510 (Pubitemid 39557511)
18. Thadikkaran L, Siegenthaler MA, Crettaz D, Queloz PA, Schneider P, Tissot JD. Recent advances in blood-related proteomics. Proteomics 2005;5:3019-3034
19. Petrakis NL. Physiologic, biochemical, and cytologic aspects of nipple aspirate fluid. Breast Cancer Res Treat 1986;8:7-19.
20. Noble J, Dua RS, Locke I, Eeles R, Gui GP, Isacke CM. Proteomic analysis of nipple aspirate fluid throughout the menstrual cycle in healthy pre-menopausal women. Breast Cancer Res Treat 2007;104:191-196 (Pubitemid 47084223)
21. Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF III. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001;17:301-307 (Pubitemid 34014685)
22. Noble JL, Dua RS, Coulton GR, Isacke CM, Gui GP. A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer. Eur J Cancer 2007;43:2315-2320
23. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, et al. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 2005;89:149-157
24. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006;52:345-351
25. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 1997;76:1106-1111
26. Soletormos G, Nielsen D, Schioler V, Mouridsen H, Dombernowsky P. Monitoring different stages of breast cancer using tumor markers CA 15-3, CEA and TPA. Eur J Cancer 2004;40:481-486
27. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002;48:1194-1197
28. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-128
29. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93:913-920
30. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999;79:300-307
31. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-325
32. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
33. Li J, Zhao J, Yu X, Lange J, Kuerer H, Krishnamurthy S, et al. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res 2005;11:8312-8320
34. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272-1275
35. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-378
36. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-356
37. Duffy MJ. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci 2006;43:325-347 (Pubitemid 43884642)
38. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-1291